Evidence map›Paper›PMID 41701410›Full record

ReviewCurrent allergy and asthma reports2026

Systemic Mastocytosis, KIT and the Effects of KIT Tyrosine Kinase Inhibitors on Mast Cell and Basophil Activation.

Peter Valent, Karin Hartmann, Gabriele Stefanzl, Yüksel Filik, Karin Bauer, Lina Degenfeld-Schonburg, Karoline V Gleixner, Frank Siebenhaar, Marek Niedoszytko, Wolfgang R Sperr and 6 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current allergy and asthma reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Peter ValentDepartment of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria. peter.valent@meduniwien.ac.at.
Karin HartmannDivision of Allergy, Department of Dermatology, University Hospital Basel and University of Basel, Basel, Switzerland.
Gabriele StefanzlDepartment of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria.
Yüksel FilikLudwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Waehringer Guertel 18-20, Vienna, A-1090, Austria.
Karin BauerLudwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Waehringer Guertel 18-20, Vienna, A-1090, Austria.
Lina Degenfeld-SchonburgDepartment of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria.
Karoline V GleixnerDepartment of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria.
Frank SiebenhaarInstitute of Allergology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Marek NiedoszytkoDepartment of Allergology, Medical University of Gdansk, Gdańsk, Poland.
Wolfgang R SperrDepartment of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria.
Narges AghaallaeiLudwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Waehringer Guertel 18-20, Vienna, A-1090, Austria.
Gregor HoermannLudwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Waehringer Guertel 18-20, Vienna, A-1090, Austria.
Vito SabatoFaculty of Medicine and Health Sciences, Department of Immunology, Allergology, Rheumatology and the Infla-Med Centre of Excellence, University of Antwerp, Antwerp, Belgium.
Alberto OrfaoDepartment of Medicine, Servicio Central de Citometria (NUCLEUS), Centro de Investigacion del Cancer (IBMCC, CSIC/USAL, Instituto Biosanitario de Salamanca (IBSAL), University of Salamanca, Salamanca, Spain.
Michel ArockDepartment of Hematological Biology, CEREMAST, Pitié- Salpêtrière Hospital, AP-HP, Paris Sorbonne University, Paris, France.
Cem AkinDivision of Allergy and Clinical Immunology, University of Michigan, Ann Arbor, MI, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSystemic mastocytosis (SM) is a protean hematologic disorder characterized by uncontrolled expansion and accumulation of tissue mast cells (MC) in various organs, including skin, bone marrow, spleen, and gastrointestinal tract. In most cases, neoplastic cells exhibit the transforming KIT mutation D816V. Clinical symptoms arise from organ infiltration by neoplastic MC and/or pro-inflammatory mediators and cytokines released by these cells. Indeed, in a majority of the patients, acute or chronic mediator-induced symptoms are recorded, and in some instances, symptoms are severe and drug-resistant or even manifest as life-threatening anaphylaxis. PURPOSE OF REVIEW: In this article, we review the role of MC and basophils in anaphylactic reactions in patients with SM and the impact of genetic variables, co-morbidities, specific IgE, and factors counteracting MC activation. Whereas avoidance of all known and potential triggers of MC activation is crucial in the management of anaphylaxis in SM patients, specific therapy is also standard, including histamine receptor blockers, other anti-mediator-type drugs and drugs suppressing MC activation and/or expansion. Novel KIT D816V-targeting drugs can potentially decrease the anaphylaxis risk by reducing the MC burden and by targeting KIT-dependent and IgE-receptor-dependent signaling processes in neoplastic MC. Application of such drugs often leads to sustained responses and an increase in the quality of life in these patients.

Indexed as

AnaphylaxisBasophilsMast CellsMastocytosis, SystemicProtein Kinase InhibitorsProto-Oncogene Proteins c-kitAnimalsHumansImmunoglobulin EMutationSignal TransductionImmunoglobulin EKIT protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins c-kitActivation SyndromeAnaphylaxisBasophilsKIT mutationsKIT Tyrosine Kinase InhibitorsMast cellMast cellsMastocytosis

Identifiers

PMID41701410
PMCPMC12913350

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.